DAPT+VKA combo linked to lower stroke risk, mortality in Afib after PCI with stent

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway 

  • Dual antiplatelet therapy (DAPT)+vitamin K antagonist is linked with lower stroke, stent thrombosis, all-cause mortality in atrial fibrillation (Afib) after percutaneous coronary intervention (PCI) vs DAPT alone but higher major bleeding risk.

Why this matters  

  • Controversy remains regarding outcomes with triple therapy vs DAPT alone following stent implantation in patients with Afib undergoing PCI.

Key results 

  • Higher major bleeding risk with triple therapy (OR, 0.62; P<.0001).
  • No differences for myocardial infarction, major adverse cardiovascular event (ORs, 1.27 and 1.17, respectively).
  • Stent thrombosis, stroke, all-cause mortality lower with triple therapy vs DAPT (ORs,...